Answers are grounded in this paper and cite their sources.
Post hoc analysis reveals improved adherence in premenopausal women via remote monitoring, suggesting valuable tools for younger patients.
Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.
No takes yet. Share an insight, caveat, or question.
Graetz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: